In multiple sclerosis (MS) beneficial effects have been assigned to the interferon (IFN)-I subclass IFN-ß, making its administration a first-line disease-modifying treatment in MS. IFN-I responses can be induced by cyclic-dinucleotide (CDN) triggered activation of Stimulator-of-interferon-genes (STING) and have essential immunomodulatory effects. A beneficial effect of STING activation on...
